Transferring Compendial Methods to UPLC Technology for Routine Generic Drug Analysis

Significance of the Topic

Generic drug manufacturers rely on compendial chromatography methods to ensure identity, potency and purity of products while minimizing costs. UPLC technology leverages sub-2-μm particles to shorten run times, reduce solvent use and boost throughput, offering a competitive edge in routine QC analysis.

Objectives and Overview

This document presents a standardized three-step workflow to transfer USP-NF HPLC methods to UPLC platforms. The approach guides method adaptation, ensuring maintained selectivity, resolution and system suitability across various generic drug formulations.

Methodology

The transfer strategy consists of:

1. Selecting a Waters HPLC column with the matching “L” designation using the Reversed-Phase Column Selectivity Chart.
2. Applying the ACQUITY UPLC Columns Calculator to downscale to a UPLC column with equivalent resolving power (constant L/dp), adjusting flow rate, injection volume and gradient profile.
3. Conducting a routine use study on the UPLC system to verify system suitability criteria for QC laboratories.

Used Instrumentation

• Waters HPLC and ACQUITY UPLC systems
• ACQUITY UPLC Columns Calculator software
• Waters Reversed-Phase Column Selectivity Chart
• Empower chromatography data software
• VanGuard Pre-Columns and 0.2 μm filters for sample and mobile phase protection

Main Results and Discussion

Chromatographic transfers maintained resolution (Rs ≈2.3) while reducing analysis times by 70–90%. Isocratic assays for levonorgestrel/ethinyl estradiol achieved equivalent separations in ~1 min versus >6 min on HPLC by increasing flow rates and decreasing injection volumes. Gradient transfers for mometasone furoate ointment required dwell-volume matching (pre-injector volume ~62 µL) to preserve selectivity. UPLC chromatograms confirmed robust peak shapes and consistent retention.

Benefits and Practical Applications

• Up to fivefold increase in sample throughput
• Solvent consumption reduced by over 90%
• Lower sample volume requirements (e.g., from 5 µL to ~1.7 µL)
• Decreased operating costs and faster QC cycles, accelerating time to market for generics

Future Trends and Potential Applications

• Expansion of UPLC adoption across all USP monographs
• Integration with automated sample preparation for higher throughput
• Application to impurity profiling, stability studies and biosimilar analysis
• Development of sub-1 μm particles and ultrahigh-pressure systems for even faster separations

Conclusion

This three-step workflow demonstrates that compendial HPLC methods can be seamlessly migrated to UPLC, realizing significant time and cost savings without compromising analytical performance. By adhering to best practices, generic drug manufacturers can enhance routine QC efficiency and reduce time to market.

Reference

1. United States Pharmacopeia–National Formulary, USP34–NF29.
2. Neue U.D. et al. Transfer of HPLC Procedures to Reduced Dimensions and Particle Sizes. Pharmacopeial Forum 2009, 35, 1622.
3. USP Monograph: Ziprasidone HCl, official May 1, 2011.
4. USP Monograph: Levonorgestrel and Ethinyl Estradiol Tablets, official August 1, 2011.
5. USP Monograph: Mometasone Furoate Ointment, official October 1, 2010.
6. Jones M.D. et al. Methods Translation between Liquid Chromatography Instrumentation. Waters Application Note 2010, Part No. 720003721EN.